MedTrace Logo

Thyroxine Therapy for Recurrent Pregnancy Loss in Hypothyroid Women

NCT06036576 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2023-09-14

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the influence of thyroxine supplementation on pregnancy outcomes in women with varying levels of Thyroid-Stimulating Hormone (TSH), who have experienced recurrent pregnancy loss in the first trimester. The main questions it aims to answer are:

* Does thyroxine treatment improve pregnancy outcomes in women with TSH levels between 2.5 mU/L and 4 mU/L?
* Is the effect of thyroxine treatment different in women with TSH levels higher than 4 mU/L?

Participants will be grouped based on their TSH levels, into two groups - those with TSH levels between 2.5 mU/L and 4 mU/L, and those with TSH levels higher than 4 mU/L. They will then be given thyroxine treatment.

Researchers will compare these two groups to see if the pregnancy outcomes differ based on the different TSH levels and thyroxine treatment.

Conditions

  • Recurrent Early Pregnancy Loss
  • Thyroid Diseases

Interventions

DRUG

Levothyroxine Pill

all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.

Sponsors & Collaborators

  • Al-Elwyiah Maternity Teaching Hospital

    collaborator UNKNOWN

  • Al-Kindy College of Medicine

    lead OTHER

Principal Investigators

  • Sarah Al-Musawi, C.A.B.O.G · Al-Kindy College of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-05-30
Completion
2023-07-20

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06036576 on ClinicalTrials.gov